Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current concepts on monoclonal gammopathies.

R A Kyle1

  • 1Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905.

Australian and New Zealand Journal of Medicine
|June 1, 1992
PubMed
Summary

Monoclonal gammopathies, involving abnormal proteins, require lifelong monitoring. A significant percentage of patients initially diagnosed with benign monoclonal gammopathy later develop serious conditions like multiple myeloma.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Medical mythology: Apollo.

Mayo Clinic proceedings·1992
Same author

Amyloidosis. Introduction and overview.

Journal of internal medicine·1992
Same author

Primary systemic amyloidosis.

Journal of internal medicine·1992
Same author

Wladyslaw Bieganski--father of modern Polish medicine.

Mayo Clinic proceedings·1992
Same author

Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients.

Archives of internal medicine·1992
Same author

Medical mythology: Hera (Juno).

Mayo Clinic proceedings·1992

Area of Science:

  • Hematology
  • Immunology

Background:

  • Monoclonal gammopathies are characterized by the production of a monoclonal protein by B lymphocytes.
  • Understanding the roles of T and B lymphocytes is crucial for diagnosing and managing these conditions.

Purpose of the Study:

  • To review monoclonal gammopathies, including their causes and the roles of lymphocytes.
  • To detail the recognition of monoclonal proteins in serum and urine.
  • To examine the long-term outcomes and differentiation between benign and malignant forms.

Main Methods:

  • Review of existing literature on monoclonal gammopathies.
  • Analysis of a long-term follow-up study of 241 patients with apparently benign monoclonal gammopathy.
  • Detailed examination of diagnostic criteria and patient monitoring.

Main Results:

  • 22% of patients with apparently benign monoclonal gammopathy developed multiple myeloma, macroglobulinaemia, amyloidosis, or related disorders over long-term follow-up.
  • The median time from monoclonal protein detection to serious disease development was 8-10 years.
  • Malignancy can develop over 20 years later, necessitating indefinite patient follow-up.

Conclusions:

  • Differentiating benign from malignant monoclonal gammopathies is critical and challenging.
  • Long-term, indefinite monitoring is essential for patients with monoclonal gammopathies due to the risk of late-onset malignancy.
  • Monoclonal gammopathies may be associated with other seemingly unrelated diseases.

Related Experiment Videos